HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TCRX
TScan Therapeutics, Inc.
TCRX lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TCRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
TCRX's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TCRX PE Valuation
TCRX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TCRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect TCRX's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TCRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.88 | +$0.23 |
| Q2 2026 | -$0.91 | +$0.17 |
| Q1 2026 | -$0.96 | +$0.12 |
| Q4 2025 | -$1.00 | +$0.14 |
TCRX has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over TCRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over TCRX on profitability, with a higher operating margin.
TCRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $586K | -77% |
| Q2 2026 | $1.1M | -66% |
| Q1 2026 | $982K | -55% |
| Q4 2025 | $2.6M | +286% |
| Q3 2025 | $2.5M | +139% |
| Q2 2025 | $3.1M | +474% |
| Q1 2025 | $2.2M | +284% |
| Q4 2024 | $665K | -91% |
TCRX's revenue has slid since its 2023 peak: $586,000 last quarter, down 77% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5637% | -4161 points |
| Q2 2026 | -2901% | -1645 points |
| Q1 2026 | -2967% | -1298 points |
| Q4 2025 | -929% | +4591 points |
| Q3 2025 | -1476% | +1634 points |
| Q2 2025 | -1257% | +5108 points |
| Q1 2025 | -1670% | +3873 points |
| Q4 2024 | -5521% | -5224 points |
TCRX's operating margin was −5637% last quarter, down 4161 points from the same quarter a year ago, near the bottom of its range since 2020.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TCRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
TCRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.1M | +$6.8M |
| Q2 2026 | -$28M | +$6.5M |
| Q1 2026 | -$24.3M | +$14.8M |
| Q4 2025 | -$32.2M | -$3.9M |
| Q3 2025 | -$33.9M | -$4.6M |
| Q2 2025 | -$34.5M | -$7.5M |
| Q1 2025 | -$39.1M | -$9.1M |
| Q4 2024 | -$28.3M | -$4.1M |
TCRX has burned cash in almost every quarter: −$112M over the past year, against −$136M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TCRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TCRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +77.1K shares |
| 1 year | +0.1% | +190K shares |
| 3 years | +175% | +82.8M shares |
| 5 years | +443% | +106M shares |
TCRX has 130M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TCRX Net Leverage
TCRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TCRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.3 | Oversold |
| Stochastic | 1.3 | Oversold |
TCRX's weekly RSI is 23 (oversold) and its Stochastic is 1 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TCRX PE vs Healthcare Sector
TCRX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TCRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.23 | 26% below |
| 20 week MA | $0.53 | 68% below |
| 50 week MA | $0.85 | 80% below |
| 100 week MA | $1.34 | 87% below |
| 200 week MA | $3.02 | 94% below |
TCRX is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over TCRX on returns for 2026, with the stronger performance.
TCRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.5 | $4.86 | -54% |
| 2022 | $4.86 | $1.51 | -69% |
| 2023 | $1.51 | $5.83 | +286% |
| 2024 | $5.83 | $3.06 | -48% |
| 2025 | $3.06 | $1.06 | -65% |
| 2026 YTD | $1.06 | $0.17 | -84% |
TCRX's yearly returns have swung widely, from +286% in 2023 to −69% in 2022. It's down 84% so far in 2026.